Trials / Completed
CompletedNCT05174182
A Comparison of Two Different Treatment Approaches for Adolescents With Osgood Schlatter
A Comparison of Two Different Treatment Approaches for Adolescents With Osgood Schlatter: A Randomized Controlled Superiority Trial (The SOGOOD Trial)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Hvidovre University Hospital · Academic / Other
- Sex
- All
- Age
- 10 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
The most common growth-related injury is Osgood Schlatter, which affects up to 1 in 5 physically active adolescents. It can cause long-term pain and potential discontinuation of sports and physical activity, with sequela well into adulthood. No effective conservative treatments have been documented, and clinical practice is characterized by a wealth of conflicting advice and modalities. A novel treatment approach has shown promising results in a small single-cohort study. Therefore, this study aims to compare this novel treatment with usual care in 10-16-year-old adolescents with Osgood Schlatter. This single-center pragmatic, double-blinded, randomized, controlled superiority trial, will have a two-group parallel arm design. Participants will undergo 3 months of treatment, followed by 2 months of self-management with self-reported knee function (KOOS-child 'Sport/rec') at 5 months as the primary endpoint. This trial comparing a novel treatment with usual care for adolescents with Osgood Schlatter could result in an evidence-based treatment ready for implementation in clinical practice, benefitting patients outcomes and clinicians.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | A novel treatment approach | A novel treatment approach, as described before. |
| OTHER | Usual care | Usual care, as described before. |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2024-03-08
- Completion
- 2024-03-08
- First posted
- 2021-12-30
- Last updated
- 2025-04-11
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05174182. Inclusion in this directory is not an endorsement.